Conference - Boston, MA, United States
With the costs of discovering and developing a new drug spiralling to over $900 M, the demand for more accurate and predictive in vitro models has never been greater.
By arming researchers with an in-depth toxicity and efficacy profile for candidate pipeline drugs, a new breed of models offer the prospect of saving drug developers millions. High potential compounds will be prioritized, animal use reduced and clinical strategy directed by progress in the predictive models field.
Realizing such immense potential will require thorough leaders to address very specific challenges. Calls to action are being made to validate the utility and practicality of 3D culture, stem cell and organ-on-a-chip models and confront attendant issues in assay development. Industry and academia also agree that more must be done to productively integrate in vitro and in vivo acquired knowledge and translate that into clinical success.
http://www.invitro-models.com/
Tue, Sep 25, 2012 - Thu, Sep 27, 2012
W Hotel, 100 Stuart Street, Boston, Massachusetts, 02116
If you'd like to ask a question or post a comment about this talk please do so below.
This seminar posting is brought to you by Biotechnology Calendar, Inc. providing access to research information and research tools for nearly 20 years. Visit our Science Market Update Blog for current science funding and market information or see our schedule of upcoming science research laboratory product shows.
